Chronic Lymphocytic Leukemia (CLL) research hub
4 indexed studies · 2 currently recruiting
- recruitingPHASE1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
This study is testing a new medicine, NX-5948, for adults with certain types of blood cancer that have come back or not responded well to previous treatments. It aims to find out if the medicine is safe and helps fight the cancer, starting with small doses and gradually increasing.
United States · France · Italy - recruitingPHASE2
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
This study looks at a new drug, NX-5948, for adults with specific types of blood cancer (CLL or SLL) that have come back or not responded to previous treatments. It aims to see how well and how safely this new drug works.
United States · France · Italy - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1 Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib or Venetoclax in Participants with Relapsed/Refractory Hematologic Malignancies
This study is testing a new drug, PRT2527, sometimes combined with other medicines. It's for adults with certain blood cancers like leukaemia and lymphoma that haven't responded to previous treatments. It aims to see if the new drug is safe and how it works.
Germany · Poland · Italy - active not recruitingPHASE1, PHASE2
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
This study is testing a new medicine called epcoritamab for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. It aims to find the right dose, understand side effects, and see how well it works.
United States · Australia · Canada